The role of inhaled corticosteroids (ICS) in COPD, examined through the lens of exacerbation phenotyping as a precision medicine approach to guide ICS use.
Exacerbation phenotyping (distinguishing eosinophilic vs. non-eosinophilic, infectious vs. non-infectious subtypes) may help identify which COPD patients are most likely to benefit from ICS, potentially reducing overuse and associated harms.
As an editorial or review-type commentary, the paper likely lacks primary trial data, direct patient-level evidence, or head-to-head phenotype-guided ICS trials to confirm clinical recommendations.
Clinicians should consider the exacerbation phenotype—particularly blood eosinophil levels and exacerbation type—before prescribing or continuing ICS in COPD patients, rather than applying ICS broadly across all COPD.